Drug sensitivity of thirty-four reference slowly growing mycobacteria to first and second line antituberculous agents
PANG Hui1, 2, 3, LI Gui-lian3, 4, WAN Kang-lin3, 4, YU Ping1
1.Department of Immunology, Xiangya School of Medicine, Central South University, Changsha 410078, China; 2.Department of Immunology, Changzhi Medical College, Changzhi 046000, China; 3.State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; 4.Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310000, China
Abstract:Slowly growing mycobacteria (SGM) are distributed in the environment, for example in soil and dirty water. SGM can cause human infections, especially lung diseases. In this article, first and second line antituberculous agents were examined in order to identify the optimum drugs for the treatment of SGM disorders. The fewest SGM in our study (4/34) were susceptible to isoniazid. Rifampicin (13/34) and ethambutol (14/34) were effective against similar numbers of strains. Ofloxacin (23/34), kanamycin (26/34), tobramycin (26/34) and streptomycin (27/34) were active against most of the tested strains. Ciprofloxacin (31/34), levofloxacin (31/34), amikacin (33/34) and capreomycin (33/34) showed an excellent range of activity. Moxifloxacin (34/34) showed the widest range of activity against the SGM species. Among the tested SGM species, M. simiae and M. africanum were resistant to the highest number of drugs. M.szulgai and M. duvalii were susceptible to all the first and second line antituberculous agents tested. Overall, the second-line antituberculous agents were good candidates for the treatment of infection by SGM species and can be widely used in the therapy of SGM diseases.
庞慧, 李桂莲, 万康林, 余平. 34株慢速生长非结核分枝杆菌针对一线和二线抗结核药物的敏感性试验研究[J]. 中国人兽共患病学报, 2015, 31(10): 914-918.
PANG Hui, LI Gui-lian, WAN Kang-lin, YU Ping. Drug sensitivity of thirty-four reference slowly growing mycobacteria to first and second line antituberculous agents. Chinese Journal of Zoonoses, 2015, 31(10): 914-918.
[1] Velayati AA, Farnia P, Mozafari M, et al. Nontuberculous mycobacteria isolation from clinical and environmental samples in Iran: twenty years of surveillance[J]. Biomed Res Int, 2015, 2015: 254285. [2] Al-Anazi KA, Al-Jasser AM, Al-Anazi WK. Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem celltransplantation[J]. Front Oncol, 2014, 4: 311. doi:10.3389/fonc.2014.00311 [3] Philley JV, Griffith DE. Treatment of slowly growing mycobacteria[J]. Clin Chest Med, 2015, 36: 79-90. [4] Ferro BE, van Ingen J, Wattenberg M, et al. Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease[J]. J Antimicrob Chemother, 2015, pii: dkv180. [5] Foongladda S, Pholwat S, Eampokalap B, et al. Multi-probe real-time PCR identification of common Mycobacterium species in blood culture broth[J]. J Mol Diagn. 2009, 11(1): 42-48. doi:10.2353/jmoldx.2009.080081 [6] Falkinham JO, Hilborn ED, Arduino MJ, et al. Epidemiology and ecology of opportunistic premise plumbing pathogens: Legionella pneumophila , Mycobacterium avium , and Pseudomonas aeruginosa [J]. Environ Health Perspect, 2015, 123(8): 749-758. [7] Hombach M, Somoskovi A, Homke R, et al. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST[J]. Int J Med Microbiol, 2013, 303 (5): 270-276. [8] Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other aerobic actinomycetes; Approved Standard Second Edition[S]. CLSI document 2011, M24-A2. [9] World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392[M]. Geneva: World Health Organization, 2008. [10] Renvoise A, Bernard C, Veziris N, et al. Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare [J]. J Clin Microbiol, 2014, 52 (12): 4439-4440. doi:10.1128/JCM.02127-14 [11] Liu G, Chen ST, Yu X, et al. Bacteriological and virulence study of a Mycobacterium chimaera isolate from a patient in China[J]. Antonie Van Leeuwenhoek, 2015, 107 (4): 901-909. [12] Venugopal D, Kumar S, Isa M, et al. Drug resistance profile of human Mycobacterium avium complex strains from India[J]. Indian J Med Microbiol, 2007 , 25 (2): 115-120. [13] Saggese MD, Tizard I, Gray P, et al. Evaluation of multidrug therapy with azithromycin, rifampin, and ethambutol for the treatment of Mycobacterium avium subsp avium in ring-neck doves ( Streptopelia risoria ): an uncontrolled clinical study[J]. J Avian Med Surg, 2014, 28 (4): 280-289. doi:10.1647/2012-067R1 [14] Jeong BH, Jeon K, Park HY, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease[J]. Am J Respir Crit Care Med, 2015, 191 (1): 96-103. doi:10.1164/rccm.201408-1545OC [15] van Ingen J, Kuijper EJ. Drug susceptibility testing of nontuberculous mycobacteria[J]. Future Microbiol, 2014, 9 (9): 1095-1110. doi:10.2217/fmb.14.60 [16] Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases[J]. Am J Respir Crit Care Med, 2007, 175 (4): 367-416. [17] Li G, Lian LL, Wan L, et al. Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate Alamar Blue assay[J]. PLoS One, 2013, 8 (12): e84065. doi:10.1371/journal.pone.0084065